San Francisco, United States
Burrill & Company deals in the field of life sciences, specifically specializing in biotechnology, pharmaceuticals, diagnostics, human healthcare technology, medical devices, nutraceuticals, wellness, agricultural biotechnology, and industrial biotechnology (biomaterials/bioprocesses). With over $500 million in management, Burrill is a life sciences merchant bank with expertise in both technical and venture investing across the spectrum of life sciences.
49
Total Investments
32
Portfolio Companies
-
Exits
2
Industries
General Information
Industries
Biotechnology, Finance
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About Burrill & Company
Recent Investments (49)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Venture Round | •••••• | Feb 2015 | |
| Series B | •••••• | Apr 2014 | |
| Series C | •••••• | Mar 2014 | |
| Series C | •••••• | May 2013 | |
| Post-IPO Equity | •••••• | Apr 2013 | |
•••• ••••
|
Series B | •••••• | Feb 2013 |
|
•••• ••••
|
Venture Round | •••••• | Feb 2013 |
|
•••• ••••
|
Series B | •••••• | Nov 2012 |
|
•••• ••••
|
Venture Round | •••••• | Oct 2012 |
|
•••• ••••
|
Post-IPO Equity | •••••• | Sep 2012 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.
